Suzanne Solman
Director
Suzanne has over 20 years of cross-functional experience in both small and large innovative pharmaceutical organizations working with biologics, biosimilars, rare disease and medical devices.
Suzanne’s strength is her breadth and depth of knowledge garnered from her professional experience in market access, pricing, PMPRB, trade relations, hospital channel, corporate start-up and understanding of the Canadian landscape.
As a Director at Pangaea, Suzanne specializes in supporting start up organizations from corporate set-up including new or transitional drug products, product importation, product assessments and Canadian environmental reviews, as well as an advisory for 3PL and PSP services. At Pangaea, Suzanne also supports PMPRB filings; her pricing experience includes new molecules, product lifecycle analysis including price increases, price decrease mitigation plans and generic entry strategy.
Areas of expertise
- Corporate Strategy
- Business Strategy
- Trade Strategy
Recent articles by Suzanne Solman
Pangaea Express: Provinces to Cut Time to Funding for Essential Cancer Medicines
December 18, 2024
Pangaea Express: PMPRB publishes a Discussion Guide
June 28, 2024
Pangaea Express: New Implications to off-patent versions of a patented drug
January 31, 2024
Pangaea Express: PMPRB Scoping Paper to Start Guidelines Discussion
November 15, 2023
Pangaea Express: PMPRB releases a statement, April 22, 2022
April 25, 2022